<- Go Home

Bachem Holding AG

Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland.

Market Cap

CHF 5.1B

Volume

112.9K

Cash and Equivalents

CHF 29.1M

EBITDA

CHF 199.7M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

CHF 211.7M

Profit Margin

31.23%

52 Week High

CHF 84.05

52 Week Low

CHF 43.34

Dividend

1.25%

Price / Book Value

3.73

Price / Earnings

37.74

Price / Tangible Book Value

3.79

Enterprise Value

CHF 5.1B

Enterprise Value / EBITDA

25.61

Operating Income

CHF 164.6M

Return on Equity

10.07%

Return on Assets

5.66

Cash and Short Term Investments

CHF 29.1M

Debt

CHF 60.9M

Equity

CHF 1.4B

Revenue

CHF 677.9M

Unlevered FCF

-CHF 227.9M

Sector

Life Sciences Tools and Services

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches